Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Yoo, Tae ^a   Lee, Woo Jin ^a   Woo, Sang Myung ^a   Kim, Tae Hyun ^a   Han, Sung Sik ^a   Park, Sang Jae ^a   Moon, Sung Ho ^a   Shin, Kyung Hwan ^a   Kim, Sang Soo ^a   Hong, Eun Kyung ^a   Kim, Dae Yong ^a   Park, Joong Won ^a  

^a National Cancer Center   (South Korea)

Author keywords

CA 19 9; Chemoradiotherapy; Distant metastasis; Overall survival; Pancreatic cancer

Indexed keywords

CHEMORADIOTHERAPY; CLINICAL PARAMETERS; COMPLETE RESPONSE; DISTANT METASTASIS; HIGH PROBABILITY; MEDIAN SURVIVAL; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PANCREATIC CANCERS; PARTIAL RESPONSE; POST TREATMENT; PRE-TREATMENT; RISK FACTORS; THREE PARAMETERS; TUMOR RESPONSE; TUMOR SIZE;

ANTIGENS; CARBOHYDRATES; DISEASES; MULTIVARIANT ANALYSIS; PATHOLOGY;

TUMORS;

CA 19-9 ANTIGEN; CAPECITABINE; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE DURATION; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TREATMENT RESPONSE; UNRESECTABLE PANCREAS CANCER;

ADULT; AGED; ANALYSIS OF VARIANCE; CA-19-9 ANTIGEN; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 80255123454     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.02.063     Document Type: Article

References (26)

1. C.G. Moertel, S. Frytak, and R.G. Hahn Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1981 1705 1710 (Pubitemid 11022870)
2. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
3. P.J. Loehrer, M.E. Powell, and H.R. Cardenes A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreastic cancer: E4201 [abstract] J Clin Oncol 26 2008 a4506
4. B. Chauffert, F. Mornex, and F. Bonnetain Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study Ann Oncol 19 2008 1592 1599
5. D.J. Klaassen, J.M. MacIntyre, and G.E. Catton Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study J Clin Oncol 3 1985 373 378 (Pubitemid 15132005)
6. D. Stefanidis, K.D. Grove, and W.H. Schwesinger The current role of staging laparoscopy for adenocarcinoma of the pancreas: A review Ann Oncol 17 2006 189 199 (Pubitemid 43160105)
7. F. Huguet, T. Andre, and P. Hammel Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 2007 326 331 (Pubitemid 350003022)
8. T. Andre, J. Balosso, and C. Louvet Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study Int J Radiat Oncol Biol Phys 46 2000 903 911 (Pubitemid 30114403)
9. C.A. Iacobuzio-Donahue, B. Fu, and S. Yachida DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
10. C.H. Crane, J.L. Abbruzzese, and D.B. Evans Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52 2002 1293 1302 (Pubitemid 34302881)
11. T. Kamisawa, T. Isawa, and M. Koike Hematogenous metastases of pancreatic ductal carcinoma Pancreas 11 1995 345 349
12. S. Krishnan, V. Rana, and N.A. Janjan Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy Cancer 110 2007 47 55 (Pubitemid 46986417)
13. H. Koprowski, Z. Steplewski, and K. Mitchell Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genet 5 1979 957 971 (Pubitemid 10132218)
14. C.R. Ferrone, D.M. Finkelstein, and S.P. Thayer Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol 24 2006 2897 2902 (Pubitemid 46630592)
15. A.C. Berger, I.M. Meszoely, and E.A. Ross Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma Ann Surg Oncol 11 2004 644 649 (Pubitemid 40486698)
16. W.S. Koom, J. Seong, and Y.B. Kim CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 73 2009 1148 1154
17. O. Micke, F. Bruns, and R. Kurowski Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy Int J Radiat Oncol Biol Phys 57 2003 90 97 (Pubitemid 36959743)
18. M. Ikeda, S. Okada, and K. Tokuuye Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy Cancer 91 2001 490 495 (Pubitemid 32105694)
19. C.J. Roche, M.L. Hughes, and C.J. Garvey CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas AJR Am J Roentgenol 180 2003 475 480 (Pubitemid 36135035)
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial JAMA 297 2007 267 277 (Pubitemid 46143304)
22. W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial JAMA 299 2008 1019 1026 (Pubitemid 351347058)
23. M. Rapellino, P. Piantino, and F. Pecchio Disappearance curves of tumor markers after radical surgery Int J Biol Markers 9 1994 33 37 (Pubitemid 24135516)
24. J.L. Magnani, Z. Steplewski, and H. Koprowski Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin Cancer Res 43 1983 5489 5492 (Pubitemid 14230170)
25. M.J. Duffy, C. Sturgeon, and R. Lamerz Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report Ann Oncol 21 2010 441 447
26. J.L. Buxbaum, and M.A. Eloubeidi Molecular and clinical markers of pancreas cancer Jop 11 2010 536 544